Analysts think CUE stock price could increase by 825%
Aug 09, 2024, 6:25 AM
-10.80%
What does CUE do
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company based in Boston, focuses on developing injectable biologics that modulate tumor-specific T cells for treating cancers and autoimmune diseases. Their lead products, including CUE-101 for HPV-driven cancers and CUE-102 targeting WT-1 protein, leverage their proprietary Immuno-STAT platform.
6 analysts think CUE stock price will increase by 825.31%. The current median analyst target is $6.12 compared to a current stock price of $0.66. The lowest analysts target is $2.02 and the highest analyst target is $8.40.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
